BPG is committed to discovery and dissemination of knowledge
Randomized Clinical Trial
Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Figure 3
Figure 3 Primary efficacy outcomes. Comparison of treatment response rate in intent-to-treat populations at week 2. Lansoprazole plus placebo: 51/82 (62.2%, 95%CI: 51.4%-71.9%); flupentixol-melitracen + lansoprazole: 71/82 (86.6%, 95%CI: 77.6%-92.3%). FM: Flupentixol-melitracen; LPZ: Lansoprazole; P + LPZ: Lansoprazole plus placebo.


Write to the Help Desk